NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
Adcendo ApS Completes $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline<
15 Apr 2026

Adcendo ApS Completes $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline

Ysios Capital joins Adcendo’s $75M Series C financing round
Ysios Capital launches InceptionBio, a €100M fund to drive biotech company creation<
27 Mar 2026

Ysios Capital launches InceptionBio, a €100M fund to drive biotech company creation

InceptionBio has completed its first closing with CDTI backing and targets the creation of at least three biotech companies by 2026.
Ysios Capital appoints Joan Perelló as Managing Partner and Arturo Urrios as Partner to drive a new early-stage vertical<
18 Mar 2026

Ysios Capital appoints Joan Perelló as Managing Partner and Arturo Urrios as Partner to drive a new early-stage vertical

New vertical focused on company creation and early-stage biotech projects, with a strong focus on Spain.
NorthSea Therapeutics Announces Achievement of Key Regulatory Milestones for Orziloben<
03 Mar 2026

NorthSea Therapeutics Announces Achievement of Key Regulatory Milestones for Orziloben

Orziloben granted Orphan Drug Designation in the U.S. and European Union.
SparingVision Successfully Completes PRODYGY Trial Patient Dosing with SPVN06, its Novel Neuroprotective Gene Therapy<
09 Feb 2026

SparingVision Successfully Completes PRODYGY Trial Patient Dosing with SPVN06, its Novel Neuroprotective Gene Therapy

The NYRVANA first-in-human trial is an open-label, multicenter, dose-escalation study investigating the safety, tolerability, and preliminary efficacy
Memo Therapeutics AG Enters into a Collaboration and Option Agreement with CSL for Development of Recombinant Polyclonal IgG Technology<
09 Feb 2026

Memo Therapeutics AG Enters into a Collaboration and Option Agreement with CSL for Development of Recombinant Polyclonal IgG Technology

Strategic research collaboration to advance MTx’s recombinant polyclonal IgG technology
Telescope Biotech Fund cierra 2025 como el Fondo de Inversión Libre más rentable del año en España<
20 Jan 2026

Telescope Biotech Fund cierra 2025 como el Fondo de Inversión Libre más rentable del año en España

El vehículo, gestionado por Andbank Wealth Management y asesorado por Ysios Capital, registra un retorno neto del 52,5% desde su lanzamiento en febrero de 2025.
Inbiomotion’s MAF Test® included in 2025 SEOM-GEICAM-SOLTI Clinical Practice Guidelines for Early-Stage Breast Cancer, further supporting its clinical utility<
15 Jan 2026

Inbiomotion’s MAF Test® included in 2025 SEOM-GEICAM-SOLTI Clinical Practice Guidelines for Early-Stage Breast Cancer, further supporting its clinical utility

A key consensus document guiding clinical decision-making in Spain and referenced internationally.
VarmX and Rentschler Biopharma partner to advance novel coagulation therapy toward Phase 3 and commercialization<
08 Jan 2026

VarmX and Rentschler Biopharma partner to advance novel coagulation therapy toward Phase 3 and commercialization

VMX‑C001 builds on strong regulatory momentum, including FDA Fast Track Designation and PMDA Phase 1 waiver, as it progresses toward a global Phase 3 trial

SpliceBio Initiates Dose-Expansion Portion of Phase 1/2 ASTRA Clinical Trial for SB-007, a Dual-AAV Gene Therapy for Stargardt Disease<
08 Jan 2026

SpliceBio Initiates Dose-Expansion Portion of Phase 1/2 ASTRA Clinical Trial for SB-007, a Dual-AAV Gene Therapy for Stargardt Disease

First dose-expansion patient successfully received SB-007

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.